Notice Regarding Joint Study Using Dietary Supplement Containing 5-Aminolevulinate Phosphate and Sodium Ferrite Citrate in Patients with Coronavirus Infection (COVID-19)29 March 2021
5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro20 January 2021
Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate, an Inducer of Heme Oxygenase 1, in Combination with Sodium Ferrous Citrate for the Treatment of COVID-19 Patients13 January 2021
Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE21 December 2020
Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications19 October 2020
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)6 November 2019
Announced the results of joint research on the development of a treatment for mitochondrial disease using 5-aminolevulinic acid and sodium ferrous citrate9 August 2019
Oral administration of 5-aminolevulinic acid induces heme oxygenase-1 expression in peripheral blood mononuclear cells of healthy human subjects in combination with ferrous iron10 May 2018
The Relationship of 5-Aminolevulinic Acid on Mood and Coping Ability in Prediabetic Middle Aged and Older Adults4 April 2018
Notice of Receipt of the Minister of Economy, Trade and Industry Award, Japan Bio-Venture Awards18 January 2017
News Page – Disclaimer
The purpose of this page is to provide you an overview of the business in the industry & market information. Information in this page are derived from internal estimates, studies, researches conducted by third parties and general publications, as well as from sources that are considered reliable, by ABBACI Health (hereinafter referred to as “producers”). Industry publications, studies, and surveys usually indicate the data used are originated from sources that are considered reliable, but no guarantee upon the accuracy or completeness of such data. Producers believe these studies and publications are safe, but they have not independently verified the market and industry data from third-party sources. Similarly, producers think that their internal researches and information about the company is reliable, but not independently validated. Therefore, the content of this prospectus and its accuracy, including the realization or reasonableness of any forecasts, management estimates, prospects or returns, are not expressed or guaranteed by the producers.
The producer is not responsible for providing updates, corrections or other new data for any of the prospectus. This page contains forecasts, as well as potential future events, possible outcomes and projected growth (collectively referred to as “forward-looking statements” or “forward-looking projections”). Producers and their employees are not responsible for relying on or using the data of
this page, or/and any liability of any nature to further convey the relevant data in writing or verbally. As this page is a confidential document, the content is strictly regulated and, without the express consent of the company or the producer, all or part of the data of this page may not be used, reproduced, transmitted, altered, published, stored, duplicated or otherwise used for any purpose.
This document is for informational purposes only and does not constitute an offer, advertisement or invitation to the public.